SUPPLEMENTARY MATERIALS

TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC
PATIENTS AND METHODS
Microtome sections (5 µM) were prepared from FFPE-tissue of NSCLC samples and one object slide was HE stained for tumor evaluation by a pathologist. Tumor tissue was gained from the remaining slides by manual microdissection, or in case material was limited, enriched by Laser Capture Microdissection (Leica CTR6500). DNA extraction was performed either manually (Macharey Nagel) or semi-automated (Maxwell MDx, Promega). Against the background of technological advances in recent years, EGFR exon 18-21 and TP53 (exons 5-9) mutational analysis were performed by direct Sanger sequencing, Cobas ® test or NGS-based methods. Alternatively, an amplicon-based NGS panel (Illumina platform) was used to detect mutations in 17 relevant genes, including TP53. Part of the samples were analyzed with a hybrid capture based target enrichment followed by massively parallel sequencing (Hybrid Capture NGS, NeoSelect, NEO New Oncology). The library preparation for the samples was performed using the Agilent SureSelect XT Kit as per the manufacturers' recommendations.
In an effort to specify the functional significance of the respective mutations in further detail, we included additional parameters in order to modify differentiation into pathogenic vs. non-pathogenic TP53 mutations. These mutations are likely to interfere with TP53 function significantly. Also, if an Align-GVGD score of C65 was reached, mutations were classified as pathogenic. Specifically, DNA-contact-mutations R273C, R273G, R248Q were reclassified as pathogenic mutations, since functional impairment is likely [2] . Mutation R280I is located within the LSH2-(loop-sheet-helix region 2), which is part of the DNA-binding core and was therefore re-categorized as pathogenic. Mutations H179R and C176S constitute Zn 2+ -binding sites and were therefore also regarded as pathogenic upon review. In addition, online protein prediction programs were used to estimate the pathogenicity of all other p53 missense changes located inside the key DNA-binding domain of p53 L1 (codons 112-141), L2 (codons 163-195), L3 (codons 236-251), LSH1 (119-135) and LSH2 (272-287).
A third classification was recently proposed by the group of Canale et al. [3] . The authors characterized a cohort of EGFR mt+ patients that in 30.1% of cases carried additional TP53 mutations and these were categorized based on exons. TP53 mutations within exon 8 were associated with significantly lower DCR, and shorter PFS and overall survival [3] . 
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